The Capital and Coast District Health Board is a district health board with the focus on providing healthcare to Wellington City, Porirua City and the Kapiti Coast in New Zealand. The CCDHB employs about 5,800 people across the Wellington Region.

During the past decade, Capital and Coast District Health Board conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 3 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 2 clinical trials were completed. i.e. 40% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Capital and Coast District Health Board" #1 sponsor was "Merck Sharp & Dohme LLC" with 2 trials, followed by "Pfizer" with 2 trials sponsored, "BeiGene" with 1 trials sponsored, "BioNTech SE" with 1 trials sponsored and "Malaghan Institute of Medical Research" with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Capital and Coast District Health Board" #1 collaborator was "Myriad Genetic Laboratories, Inc." with 1 trials as a collaborator, "Pfizer" with 1 trials as a collaborator, "Pierre Fabre Laboratories" with 1 trials as a collaborator, "Royal Children's Hospital" with 1 trials as a collaborator and "Wellington Zhaotai Therapies Limited (WZTL)" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Capital and Coast District Health Board" are "Arteriovenous Fistula" (1 trials), "Arteriovenous Fistula Occlusion" (1 trials), "Arteriovenous Fistula Stenosis" (1 trials), "COVID-19" (1 trials) and "Carcinoma, Non-squamous Non-small-cell Lung" (1 trials). Many other conditions were trialed in "Capital and Coast District Health Board" in a lesser frequency.

Most popular intervention types in "Capital and Coast District Health Board" are "Biological" (6 trials), "Drug" (5 trials), "Other" (2 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Carboplatin" (2 trials), "Olaparib" (2 trials), "Pembrolizumab" (2 trials), "Placebo" (2 trials) and "Adalimumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Capital and Coast District Health Board" are 9 trials for "All" genders.

Currently, there are NaN active trials in "Capital and Coast District Health Board". undefined are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Capital and Coast District Health Board, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Capital and Coast District Health Board, 3 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".

Capital and Coast District Health Board has several departments that took part in Clinical trials: "Wellington Cancer Centre" - 8 trials, "Wellington Hospital; Department of Neurology" - 3 trials, "Diabetes Centre" - 2 trials, "Endocrine, Diabetes and Research Centre, Wellington Hospital" - 2 trials